Jordyn Sava is an editor for Targeted Oncology.
Positive Survival Outcomes With/ Without Paclitaxel in Patients With HER2+ Breast Cancer
May 5th 2022Survival rates for patients with different subtypes of early breast cancer who had a pathological complete response after de-escalated 12-week trastuzumab plus pertuzumab with or without weekly paclitaxel are promising.
Ribociclib Demonstrates Promising OS Benefit in HR+/HER2- Advanced Breast Cancer
May 4th 2022Combination of ribociclib plus fulvestrant achieved a median overall survival of 67.6 months in the first-line setting for patients with postmenopausal, hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer.
Dosing of KIN-3248 Begins in Advanced Solid Tumors With FGFR2 and/or FGFR3 Alterations
May 2nd 2022The first patient has been dosed in the phase 1 KN-4802 trial examining the safety, tolerability, and preliminary efficacy of KIN-3248 in adult patients with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations.
Larotrectinib Efficacy Withstands Various NTRK Gene Fusions in Non-Primary CNS TRK Fusion+ Cancer
May 1st 2022In an interview with Targeted Oncology, Marc Ladanyi, MD, discussed pooled data of larotrectinib in patients with NTRK fusion-positive cancers and how variability in NTRK gene fusions impacts outcomes.
FDA’s ODAC Votes Yes to Requiring Randomized Data for Future PI3Ki Approvals in Hematologic Cancers
April 21st 2022In a 16 to 0 vote, the FDA’s Oncologic Drugs Advisory Committee has voted yes to future approvals of PI3K inhibitors being supported by randomized data given observed toxicities in the drug class, research showing a detriment in OS, a narrow range between effective, and toxic doses.
FDA Approval Application for U2 Regimen in CLL and SLL Voluntarily Withdrawn
April 18th 2022With an increasing imbalance in overall survival, the FDA approval application for the combination of ublituximab and umbralisib for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma has been withdrawn.